Biogen Discontinues Development of Cinpanemab

Biogen Discontinues Development of Cinpanemab

285246

Biogen Discontinues Development of Cinpanemab

Due to negative clinical trial findings, Biogen has discontinued the development of cinpanemab (BIIB054), an investigational medication intended to treat Parkinson’s disease, the company announced in its 2020 investors report. Cinpanemab is a human-derived antibody that targets alpha-synuclein, thought to be one of the key hallmarks of Parkinson’s disease. In the brains of people with Parkinson’s disease, there often are protein clumps predominantly composed of alpha-synuclein; these clumps, typically referred to as “aggregates,” are thought to drive disease…

You must be logged in to read/download the full post.